Display options
Cite
Miravitlles M, Zalacain R, Murio C, et al. Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials : results of a two-year study. Clin Drug Investig. 2003;23(7):439-50doi: 10.2165/00044011-200323070-00003.
Miravitlles, M., Zalacain, R., Murio, C., Ferrer, M., Alvarez-Sala, J. L., Masa, J. F., Verea, H., Ros, F., Vidal, R. (2003). Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials : results of a two-year study. Clinical drug investigation, 23(7), 439-50. https://doi.org/10.2165/00044011-200323070-00003
Miravitlles, Marc, et al. "Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials : results of a two-year study." Clinical drug investigation vol. 23,7 (2003): 439-50. doi: https://doi.org/10.2165/00044011-200323070-00003
Miravitlles M, Zalacain R, Murio C, Ferrer M, Alvarez-Sala JL, Masa JF, Verea H, Ros F, Vidal R. Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials : results of a two-year study. Clin Drug Investig. 2003;23(7):439-50. doi: 10.2165/00044011-200323070-00003. PMID: 17535055.
Copy Download .nbib Format: NLM
Share it on

Clin Drug Investig. 2003;23(7):439-50. doi: 10.2165/00044011-200323070-00003.

Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials : results of a two-year study.

Clinical drug investigation

Marc Miravitlles, Rafael Zalacain, Cristina Murio, Montserrat Ferrer, José L Alvarez-Sala, Juan F Masa, Héctor Verea, Fernando Ros, Rafael Vidal,

Affiliations

  1. Servei de Pneumologia, Institut Clínic de Pneumologia i Cirurgia Toràcica (IDIBAPS), Hospital Clinic i Provincial, Barcelona, Spain.

PMID: 17535055 DOI: 10.2165/00044011-200323070-00003

Abstract

OBJECTIVE: We performed a multicentre study under a 2-year observational protocol that included data on time to recovery from acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) in patients receiving moxifloxacin and comparator antimicrobials.

PATIENTS AND METHODS: Outpatients with moderate or severe COPD were recruited from respiratory clinics throughout Spain. Moxifloxacin was available in year 2, and was to be prescribed to 50% of patients in that period in a non-randomised allocation. Time to recovery was compared in successfully treated AE-COPD; cross-sectionally for all AE-COPD over 2 years, first AE-COPD and all AE-COPD in year 2, and longitudinally in patients receiving comparator antimicrobials for AE-COPD in year 1 and moxifloxacin in year 2.

RESULTS: 614 AE-COPD were treated in 441 patients over 2 years (mean age 66.7 +/- 8.3 years, 98% males, mean forced expiratory volume in 1 second [FEV(1)] 35.9 +/- 8.8%). Mean time to recovery overall was 4.6 days (SD 3.3) with moxifloxacin 400 mg/day for 5 days, and 5.8 days (SD 4.6) with comparators (p < 0.01), which were most frequently amoxicillin/clavulanic acid 500/125mg/8h, clarithromycin 500mg/12h and cefuroxime axetil 500mg/12h for 7-10 days. Longitudinal analysis showed that 27 patients treated with moxifloxacin in the second year of the study recovered in a mean of 3.7 days (SD 3.1), and the same patients treated with comparator antimicrobials in year one recovered in a mean of 6.8 days (SD 4.6) [p = 0.02]. In contrast, in 66 patients treated with comparator antimicrobials in both years, mean time to recovery was 7.4 days (SD 7.3) in year one and 5.5 days (SD 3.5) in year two (p = 0.24). All subgroup analyses showed a statistically significant reduction of 18-25% in time to recovery with moxifloxacin compared with other antibiotics.

CONCLUSIONS: Moxifloxacin significantly reduced time to recovery from AE-COPD in patients with moderate to severe disease by approximately 20% (>1 day) compared with other antimicrobials. Faster recovery should result in earlier return to work or normal activities, and to social and economic savings.

References

  1. Chest. 1999 Jul;116(1):40-6 - PubMed
  2. Arch Bronconeumol. 2001 Jul-Aug;37(7):269-78 - PubMed
  3. N Engl J Med. 1999 Nov 11;341(20):1546-7; author reply 1547-8 - PubMed
  4. Am Rev Respir Dis. 1986 May;133(5):814-9 - PubMed
  5. J Int Med Res. 2001 Mar-Apr;29(2):74-86 - PubMed
  6. Int J Antimicrob Agents. 2002 Feb;19(2):119-23 - PubMed
  7. Chest. 2000 May;117(5):1345-52 - PubMed
  8. Chest. 2000 Mar;117(3):662-71 - PubMed
  9. Respir Med. 1999 Mar;93(3):173-9 - PubMed
  10. Respir Med. 2002 Jan;96(1):39-51 - PubMed
  11. J Antimicrob Chemother. 2001 Feb;47(2):215-8 - PubMed
  12. Respiration. 2000;67(5):495-501 - PubMed
  13. Chest. 1998 Apr;113(4 Suppl):249S-255S - PubMed
  14. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418-22 - PubMed
  15. Thorax. 1999 Jul;54(7):581-6 - PubMed
  16. J Int Med Res. 2001 Mar-Apr;29(2):61-73 - PubMed
  17. Antimicrob Agents Chemother. 2002 Feb;46(2):522-4 - PubMed
  18. Am Rev Respir Dis. 1991 Nov;144(5):1202-18 - PubMed
  19. Int J Clin Pract. 2001 Sep;55(7):437-41 - PubMed
  20. Antimicrob Agents Chemother. 1998 Jun;42(6):1397-407 - PubMed
  21. Eur Respir J. 2001 May;17(5):928-33 - PubMed
  22. Eur J Haematol. 2001 May;66(5):287-96 - PubMed
  23. Eur J Clin Microbiol Infect Dis. 2000 Mar;19(3):228-32 - PubMed
  24. Clin Infect Dis. 2001 May 15;32 Suppl 2:S81-93 - PubMed
  25. Chest. 1998 Jan;113(1):131-41 - PubMed
  26. J Antimicrob Chemother. 1999 Dec;44(6):835-8 - PubMed
  27. Ann Intern Med. 1987 Feb;106(2):196-204 - PubMed
  28. J Antimicrob Chemother. 2001 Jun;47(6):811-8 - PubMed
  29. Am J Respir Crit Care Med. 1995 Nov;152(5 Pt 2):S77-121 - PubMed
  30. Qual Life Res. 2002 Jun;11(4):329-38 - PubMed
  31. J Int Med Res. 2001 Mar-Apr;29(2):51-60 - PubMed
  32. Manag Care Interface. 2001 Feb;14(2):52-9 - PubMed
  33. Chest. 2002 May;121(5):1449-55 - PubMed
  34. Chest. 2000 Oct;118(4):981-9 - PubMed
  35. Clin Ther. 2002 Apr;24(4):639-52 - PubMed
  36. N Engl J Med. 1999 Jul 22;341(4):233-9 - PubMed
  37. Antimicrob Agents Chemother. 2001 Feb;45(2):433-8 - PubMed
  38. J Antimicrob Chemother. 1999 May;43 Suppl B:1-11 - PubMed
  39. Ann Intern Med. 1997 Dec 15;127(12):1072-9 - PubMed
  40. JAMA. 1995 Mar 22-29;273(12):957-60 - PubMed
  41. Respir Med. 2000 Nov;94(11):1029-37 - PubMed
  42. Am J Respir Crit Care Med. 2001 Aug 1;164(3):358-64 - PubMed

Publication Types